The FDA permitted marketing of Hemospray, a new endoscopic device for the treatment of gastrointestinal bleeding. Here are five things to know. 1. The FDA permitted Wilson-Cook Medical to market the ...
In the study of over 200 patients, 90.1% of those who received TC-325 had their bleeding controlled within 30 days, as compared to 81.4% of those who received standard treatment, meeting criteria for ...
FORT LAUDERDALE, Fla., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company focused on improving endoscopic outcomes and ...
Gastroenterologists concerned over the management of anticoagulant and antiplatelet drugs during gastrointestinal (GI) procedures now have new guidance in the first set of recommendations to be ...
Patients who suffer a GI bleed after PCI are a challenging group. They may have multiple comorbidities and are often medically unstable; treatment must balance the need to prevent ischemic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback